Incidence of Richter Transformation of Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma in the Targeted Therapy Era

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2024 Dec 10

PMID 39658628

Authors

Paul J Hampel

Kari G Rabe

Yucai Wang

Steven R Hwang

Saad S Kenderian

Eli Muchtar

Jose F Leis

Amber B Koehler

Mazie Tsang

Talal Hilal

Ricardo Parrondo

Rachel J Bailen

Susan M Schwager

Curtis A Hanson

Esteban Braggio

Susan L Slager

Min Shi

Cinthya J Zepeda-Mendoza

Daniel L Van Dyke

Tait D Shanafelt

Rebecca L King

Timothy G Call

Neil E Kay

Wei Ding

Sameer A Parikh

Affiliations

Soon will be listed here.

Citing Articles

Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.

Maher N, Mouhssine S, Matti B, Alwan A, Gaidano G Cancers (Basel). 2025; 17(5).

PMID: 40075754 PMC: 11899122. DOI: 10.3390/cancers17050907.

References

Rossi D, Spina V, Gaidano G . Biology and treatment of Richter syndrome. Blood. 2018; 131(25):2761-2772. DOI: 10.1182/blood-2018-01-791376. View

Parikh S, Kay N, Shanafelt T . How we treat Richter syndrome. Blood. 2014; 123(11):1647-57. PMC: 3954047. DOI: 10.1182/blood-2013-11-516229. View

Parikh S, Rabe K, Call T, Zent C, Habermann T, Ding W . Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013; 162(6):774-82. PMC: 4098845. DOI: 10.1111/bjh.12458. View

Lenartova A, Randen U, Johannesen T, Tjonnfjord G . Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway. Cancer Epidemiol. 2019; 60:128-133. DOI: 10.1016/j.canep.2019.04.002. View

Al-Sawaf O, Robrecht S, Bahlo J, Fink A, Cramer P, V Tresckow J . Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 2020; 35(1):169-176. DOI: 10.1038/s41375-020-0797-x. View

Anderson M, Tam C, Lew T, Juneja S, Juneja M, Westerman D . Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 2017; 129(25):3362-3370. DOI: 10.1182/blood-2017-01-763003. View

Maddocks K, Ruppert A, Lozanski G, Heerema N, Zhao W, Abruzzo L . Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015; 1(1):80-7. PMC: 4520535. DOI: 10.1001/jamaoncol.2014.218. View

Eichhorst B, Niemann C, Kater A, Furstenau M, von Tresckow J, Zhang C . First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med. 2023; 388(19):1739-1754. DOI: 10.1056/NEJMoa2213093. View

Shanafelt T, Wang X, Hanson C, Paietta E, OBrien S, Barrientos J . Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022; 140(2):112-120. PMC: 9283968. DOI: 10.1182/blood.2021014960. View

10.

Sharman J, Egyed M, Jurczak W, Skarbnik A, Pagel J, Flinn I . Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020; 395(10232):1278-1291. PMC: 8151619. DOI: 10.1016/S0140-6736(20)30262-2. View

11.

Woyach J, Ruppert A, Heerema N, Zhao W, Booth A, Ding W . Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018; 379(26):2517-2528. PMC: 6325637. DOI: 10.1056/NEJMoa1812836. View

12.

Nadeu F, Royo R, Massoni-Badosa R, Playa-Albinyana H, Garcia-Torre B, Duran-Ferrer M . Detection of early seeding of Richter transformation in chronic lymphocytic leukemia. Nat Med. 2022; 28(8):1662-1671. PMC: 9388377. DOI: 10.1038/s41591-022-01927-8. View